Journal of Lipid Research, Vol 33, 1657-1663, Copyright © 1992 by Lipid Research, Inc.

ARTICLES

Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis

D Amin, SA Cornell, SK Gustafson, SJ Needle, JW Ullrich, GE Bilder and MH Perrone
Department of Cardiovascular Biology, Rhone-Poulenc Rorer Central Research, Collegeville, PA 19426-0107.

Some bisphosphonates used for the treatment of bone disorders are also potent inhibitors of squalene synthase, a critical enzyme for sterol biosynthesis. Among seven drugs tested, YM 175 (cycloheptylaminomethylene-1,1-bisphosphonic acid) was the most potent inhibitor of rat liver microsomal squalene synthase (Ki = 57 nM) and sterol biosynthesis from [14C]mevalonate in rat liver homogenate (IC50 = 17 nM). EB 1053 (3-(1-pyrolidino)-1-hydroxypropylidene-1,1- bisphosphonic acid) and PHPBP (3-(1-piperidino)-1-hydroxypropylidene- 1,1-bisphosphonic acid) were less potent inhibitors in both these assays. Pamidronate and alendronate were poor inhibitors of squalene synthase (IC50 > 10 microM) but were potent inhibitors of sterol biosynthesis from mevalonate (IC50 = 420 and 168 nM, respectively), suggesting that the latter two agents may have inhibited other enzymes involved in the synthesis of farnesyl pyrophosphate from mevalonate. Etidronate and clodronate were inactive in both these assays. YM 175 also inhibited sterol biosynthesis in mouse macrophage J774 cells (IC50 = 64 microM) and in rats, when administered acutely, it inhibited cholesterol biosynthesis in the liver (ED50 = 30 mg/kg, s.c.). Structural modifications on YM 175 to enhance cell permeability may result in a new class of cholesterol-lowering agents.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D.B. Kimmel Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates J. Dent. Res., November 1, 2007; 86(11): 1022 - 1033. [Abstract] [Full Text] [PDF]

				R. G. G. Russell Bisphosphonates: Mode of Action and Pharmacology Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162. [Abstract] [Full Text] [PDF]

				C. L. Navarro, P. Cau, and N. Levy Molecular bases of progeroid syndromes Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R151 - R161. [Abstract] [Full Text] [PDF]

				R. G. G. RUSSELL Bisphosphonates: From Bench to Bedside Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 367 - 401. [Abstract] [Full Text] [PDF]

				C. D. Morris and T. A. Einhorn Bisphosphonates in Orthopaedic Surgery J. Bone Joint Surg. Am., July 1, 2005; 87(7): 1609 - 1618. [Abstract] [Full Text] [PDF]

				H L Neville-Webbe and R E Coleman The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia Palliative Medicine, September 1, 2003; 17(6): 539 - 553. [Abstract] [PDF]

				G. A. Rodan and A. A. Reszka Osteoporosis and Bisphosphonates J. Bone Joint Surg. Am., August 1, 2003; 85(90003): 8 - 12. [Full Text] [PDF]

				F. P. Coxon, M. H. Helfrich, B. Larijani, M. Muzylak, J. E. Dunford, D. Marshall, A. D. McKinnon, S. A. Nesbitt, M. A. Horton, M. C. Seabra, et al. Identification of a Novel Phosphonocarboxylate Inhibitor of Rab Geranylgeranyl Transferase That Specifically Prevents Rab Prenylation in Osteoclasts and Macrophages J. Biol. Chem., December 14, 2001; 276(51): 48213 - 48222. [Abstract] [Full Text] [PDF]

				J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, and M. J. Rogers Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 235 - 242. [Abstract] [Full Text]

				A. A. Reszka, J. Halasy-Nagy, and G. A. Rodan Nitrogen-Bisphosphonates Block Retinoblastoma Phosphorylation and Cell Growth by Inhibiting the Cholesterol Biosynthetic Pathway in a Keratinocyte Model for Esophageal Irritation Mol. Pharmacol., February 1, 2001; 59(2): 193 - 202. [Abstract] [Full Text]

				G. G. Reinholz, B. Getz, L. Pederson, E. S. Sanders, M. Subramaniam, J. N. Ingle, and T. C. Spelsberg Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, and Gene Expression in Human Osteoblasts Cancer Res., November 1, 2000; 60(21): 6001 - 6007. [Abstract] [Full Text]

				J. A. Urbina, B. Moreno, S. Vierkotter, E. Oldfield, G. Payares, C. Sanoja, B. N. Bailey, W. Yan, D. A. Scott, S. N. J. Moreno, et al. Trypanosoma cruzi Contains Major Pyrophosphate Stores, and Its Growth in Vitro and in Vivo Is Blocked by Pyrophosphate Analogs J. Biol. Chem., November 19, 1999; 274(47): 33609 - 33615. [Abstract] [Full Text] [PDF]

				J. E. Fisher, M. J. Rogers, J. M. Halasy, S. P. Luckman, D. E. Hughes, P. J. Masarachia, G. Wesolowski, R. G. G. Russell, G. A. Rodan, and A. A. Reszka Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro PNAS, January 5, 1999; 96(1): 133 - 138. [Abstract] [Full Text] [PDF]

				D. Amin, R. Z. Rutledge, S. N. Needle, H. F. Galczenski, K. Neuenschwander, A. C. Scotese, M. P. Maguire, R. C. Bush, D. J. Hele, G. E. Bilder, et al. RPR 107393, a Potent Squalene Synthase Inhibitor and Orally Effective Cholesterol-Lowering Agent: Comparison with Inhibitors of HMG-CoA Reductase J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 746 - 752. [Abstract] [Full Text]